Publications by authors named "Aurore Delvenne"
Background: Structural and functional changes of the choroid plexus (ChP) have been reported in Alzheimer's disease (AD). Nonetheless, the role of the ChP in the pathogenesis of AD remains largely unknown. We aim to unravel the relation between ChP functioning and core AD pathogenesis using a unique proteomic approach in mice and humans.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the role of neurodegeneration markers (neurogranin, neurofilament light, and hippocampal volume) in Alzheimer's disease using cerebrospinal fluid proteomics.
- A small number of individuals exhibited both amyloid and tau pathology with either neurogranin or neurofilament light, showing distinct proteomic profiles based on these markers.
- The findings suggest that neurogranin might not be the best indicator of neurodegeneration and that different markers provide unique insights into the disease, helping refine staging beyond just amyloid and tau levels.
The development of biomarkers for Alzheimer disease (AD) has led to the origin of suspected non-AD pathophysiology (SNAP) - a heterogeneous biomarker-based concept that describes individuals with normal amyloid and abnormal tau and/or neurodegeneration biomarker status. In this Review, we describe the origins of the SNAP construct, along with its prevalence, diagnostic and prognostic implications, and underlying neuropathology. As we discuss, SNAP can be operationalized using different biomarker modalities, which could affect prevalence estimates and reported characteristics of SNAP in ways that are not yet fully understood.
View Article and Find Full Text PDFBackground: Suspected non-Alzheimer's disease pathophysiology (SNAP) is a biomarker concept that encompasses individuals with neuronal injury but without amyloidosis. We aim to investigate the pathophysiology of SNAP, defined as abnormal tau without amyloidosis, in individuals with mild cognitive impairment (MCI) by cerebrospinal fluid (CSF) proteomics.
Methods: Individuals were classified based on CSF amyloid beta (Aβ)1-42 (A) and phosphorylated tau (T), as cognitively normal A-T- (CN), MCI A-T+ (MCI-SNAP), and MCI A+T+ (MCI-AD).